GyorgyMarko-Varga Lund UniversitySweden

György Marko-Varga (GMV) is a leading scientist in Clinical Protein Science and Imaging, with more than 19 years at AstraZeneca in Sweden and Japan, where he held senior Discovery and R&D roles, bringing 2 drug products to the market. He is Professor at Lund University and Head of Clinical Protein Science and Imaging, integrating proteomics, digital pathology, and translational medicine. With 445 publications, more than 19,500 citations, an H-index of 70, an additional 22 patents, as well as the Research.com Chemistry Leader Award (2023 and 2024). GMVs early collaboration with Nobel Laureate Bengt Samuelsson shaped his expertise in inflammation biology. Appointed Director of the European Cancer Moonshot Center at Lund University in 2017, he leads large-scale clinical ProteoGenomic programs supported by multi-million–sample biobanks and an ongoing MEGA melanoma study comprising 3,000 tumors. GMV has served as Principal Investigator or key scientific lead in 15 cancer studies over the past decade, demonstrating sustained leadership in translational oncology research. With a strong AI-driven strategy, his team has published and developed 10 dedicated AI studies integrating digital pathology, AI-Imaging, spatial proteomics, and clinical diagnosis studies. These machine learning frameworks enable tumor stratification, immune mapping, and therapy-response prediction at single-cell resolution. By transforming multi-omics data into clinically actionable decision-support systems, the program advances precision oncology and embeds AI-guided treatment optimization into real-world cancer care. GMV´s team are the first in the world to report on predictive treatment strategies with AI-Imaging/Digital Pathology/Functional Genomics/Clinical Meta-Data interfaced algorithms applied to a Cancer patient.